blinatumomab bi-specific t-cell engager (bite) drug. targets cd19 and cd3; indicated for the treatment of acute lymphoblastic

acute all antibody bcell biological biosimilar biotech biotechnology bispecific bite blinatumomab cd19 cd3 chromosome disease drug engager immunoglobulin immunology infusion injection inn leukemia lymphoblastic mab malignant monoclonal nomenclature oncology peptide philadelphia protein tcell